Evidence map›Paper›PMID 40610683›Full record

ArticleNPJ digital medicine2025

A GPT-4o-powered framework for identifying cognitive impairment stages in electronic health records.

Yu Leng, Yingnan He, Samad Amini, Colin Magdamo, Ioannis Paschalidis, Shibani S Mukerji, Lidia M V R Moura, M Brandon Westover, Ana-Maria Vranceanu, Christine S Ritchie and 3 more

Abstract read
In one paragraph

Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yu Leng *Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Yingnan He *Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Samad AminiBoston University, Boston, MA, USA.
Colin MagdamoDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Ioannis PaschalidisBoston University, Boston, MA, USA.
Shibani S MukerjiDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Lidia M V R MouraDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
M Brandon WestoverHarvard Medical School, Boston, MA, USA.
Ana-Maria VranceanuHarvard Medical School, Boston, MA, USA.
Christine S RitchieHarvard Medical School, Boston, MA, USA.
Deborah BlackerHarvard Medical School, Boston, MA, USA.
John R DicksonDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Sudeshna DasDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA. sdas5@mgh.harvard.edu.

Funding

Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI STEVEN E ARNOLD · 2019 to 2026
$36.5M
A deep learning algorithm to detect signs of cognitive impairment in electronic health recordsR01AG082698 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Sudeshna Das · 2024 to 2026
$2.1M
NIA NIH HHS P30 AG062421NIA NIH HHS R01 AG082698NIA NIH HHS R01AG082698NIH HHS R01AG082698
6 · The paper itself

Abstract

Alzheimer's Disease and Related Dementias (ADRD) pose a major public health challenge, with a critical need for accurate and scalable tools for detecting cognitive impairment (CI). Readily available electronic health records (EHRs) contain valuable cognitive health data, but much of it is embedded in unstructured clinical notes. To address this problem, we developed a GPT-4o-powered framework for CI stage classification, leveraging longitudinal patient history summarization, multi-step reasoning, and confidence-aware decision-making. Evaluated on 165,926 notes from 1002 Medicare patients from Mass General Brigham (MGB), our GPT-4o framework achieved high accuracy in CI stage classification (weighted Cohen's kappa = 0.95, Spearman correlation = 0.93), and outperformed two other language models (weighted Cohen's kappa 0.82-0.85). Our framework also achieved high performance on Clinical Dementia Rating (CDR) scoring on an independent dataset of 769 memory clinic patients (weighted Cohen's kappa = 0.83). Finally, to ensure reliability and safety, we designed an interactive AI agent integrating our GPT-4o-powered framework and clinician oversight. This collaborative approach has the potential to facilitate CI diagnoses in real-world clinical settings.

Identifiers

PMID40610683
PMCPMC12229571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.